Are you having trouble sourcing BSA and BGG? – Proliant can help
As the world’s largest manufacturer of animal-derived proteins, we provide the highest levels of consistency, traceability, and quality in the market. With facilities in the U.S. and New Zealand, we have sustainable supply practices in place to help alleviate sourcing headaches, whether you’re in medical device manufacturing, in-vitro diagnostics, therapeutics, vaccine production, biopharmaceuticals, nutraceuticals, or any other number of life science research industries.
|
|
BioPharmGuy
If your company wants to sell to biotech companies, you need the right tools. Our directory and the data we have available could be a big help to your sales and marketing team. Drug pipeline info, funding rounds, executive emails, addresses, phone numbers - some might say it's a salesperson's dream. (Ok, we're probably the only ones dreaming about a biotech company database)
To answer some common questions about our data:
1) Yes, it's that good
2) Yes, the price is that reasonable
We run a streamlined operation - no app, no fancy user interface, very few futuristic website features (ok, none). We maintain this biotech directory - everything else is ancillary, though this newsletter is a fun diversion.
What else? No price discrimination - everyone gets the same price. We deliver an Excel file, so it can be imported into your Salesforce or whatever pretty easily.
Animal inquiry of the week
Someone contacted us about a hoard of scorpion venom they were trying to move. They even dropped some scorpion handling knowledge on us:
“Scorpions are kept at the separate lanterns before the milking process. They are milked with the innovative methods and the milked venom is stored under the appropriate condition.”
These days it’s refreshing to hear of someone using the innovative scorpion milking methods – far too many scorpion venom producers are stuck in the past with their outdated milking methods. It's a blight on the entire scorpion venom industry!
Long story short, if you find yourself in need of scorpion venom, we got a guy.
Companies Added & Removed
40 new companies added this week, three removed.
Best New Name with a Y-substituted letter:
Worst New Name with a Y-substituted letter:
Most Boring:
Most Reddity:
Summary file of additions and removals available on our downloads page.
|
|
Bloodletting Continues
In what is probably a precursor of what's to come, dozens of biotechs have laid off employees recently. It’s interesting since there is simultaneously a dearth of qualified talent available. These strange circumstances are due to the fact that there are too many biotech companies out there in the first place.
If you signed up for the biotech industry, you should have known this was part of the game. Polish up those resumes and always be ready to start searching. But then again, weekly unemployment maximum in Massachusetts is 50% of wages up $974, so maybe you’re down for a little paid vacation? Different story out west, though - in California the weekly maximum is $450. Yuck.
New in the Zoo
We are happy to announce the newest member of our BioPharmZoo – Ocelot Bio. They launched with $36M to hopefully treat complications of end-stage liver disease.
The wild ocelot ranges from the southwestern US into South America and also lives on Trinidad as well as the Venezuelan island of Margarita. A medium-sized cat surviving on a human-populated, 390 square mile island is impressive. We need more Ocelot sports mascots.
Moderna
A full year after the original vaccines were approved for adults, Moderna is finally applying for an EUA on its vaccine for children 6 mos - 5 yrs. The Pfizer/BioNTech vaccine failed to elicit a strong immune reaction in the young, so this would be the first approved for that age group.
This isn't bad news, but also at this point every kid that age pretty much already got Covid, and children were the least impacted of any age group. Either way, this study could be informative for whenever Moderna finally changes their product to be future variant-specific.
Speaking of, why are they not already making a new version? Easy answer – the government isn’t paying them to do it. Moderna is a for-profit drug company, so they're not going to spend a bunch of money developing a drug that may end up going unused. They’ve gone on and on about how they can quickly switch to a different RNA sequence if needed, but they’ve really oversold that to the media. It will still take a while, and just because the formulation and everything went well last time doesn’t mean next time will be easy street. Then you have clinical studies...this all takes time. Let's hope we don't suddenly need it.
Immorna Therapeutics
This company is working on a therapy dubbed “self-replicating mRNA”. Their first product is meant to produce IL-12 in patients. IL-12 is a cytokine that has cancer-attacking capabilities. But any cytokine in humans also has the potential to have deleterious effects if overproduced.
In that light, self-replicating therapies kind of sound freaky to us and we know what we're talking about. Imagine what the Internet bozos will say. What's especially disconcerting is cancer itself is an uncontrolled self-replicating beast.
Work like this, if conducted poorly, has the potential to dynamite this whole area of exploration before it even gets going. That's kind of what happened to cell therapy back in 1999.
|
|
Gamma, e-beam, or x-ray? Considerations for sterilization and bioburden control of medical devices and single-use systems
Today, new approaches to irradiation are required to close the gap between expected demand increases and available supply.
Get valuable insights into gamma, e-beam and x-ray sterilization modalities and regulatory considerations. Learn about comparatives studies by leading academic and trade organizations and the conclusions they draw on sterilization techniques.
|
|
Covid Update
For all age groups, save the very old, Covid hospitalization rates in America are the lowest they’ve been for the entire pandemic. Case counts have flatlined near all-time lows and death rates are still on a downward trend. Covid is here to stay, but if it stays like this, that’s reason to celebrate.
Covid Challenge
Imperial College London researchers have published the results of their Covid challenge study. 36 volunteers were deliberately challenged with the OG Covid strain which led to 18 becoming infected. It took about two days for people to become contagious, a bit longer to be symptomatic. 83% of the infected at least partially lost their sense of smell, one of whom still had not regained their sense of smell after six months.
This is all well and good for basic research purposes, but with how the virus has mutated, not sure this tells us anything useful. Funny enough, the researchers are planning a new study – on the now all-but-extinct Delta virus.
That Other Epidemic
The US house passed a measure limiting patient co-pays on a month’s supply of insulin to $35. The Senate probably won’t play ball, but this political health care cost whack-a-mole might be a minor vote winner for Democrats, especially when at least one Republican implied he voted against it because people should lose some weight instead. Bold tactic there, to say the least – in America, the right to be unhealthy is pretty much the 11th amendment.
Even if this somehow passes the Senate, lower co-pays on insulin will mean higher co-pays on everything else. That’s a net win for people on insulin, net loss for everyone else, all while the health care labyrinth gets more dizzying.
|
|
BioPharmGuy is a registered trademark of Wilsonian LLC, Content © 2022 Wilsonian LLC |
|
Check your website's analytics - we are likely one of your top referrers. You may be able to boost those referrals with a Premium Listing. Read more here: Promoted Listings.
Send us a message if you have questions or are interested.
|
|
|
|
|
|
|
|
